ArticleInternational urology and nephrology2026
Chronic kidney disease due to hypertension in China, Japan, and the Republic of Korea: trends from the Global Burden of Disease Study 1990-2023.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the burden and temporal trends of chronic kidney disease (CKD) attributable to hypertension in China, Japan, and the Republic of Korea from 1990 to 2023 using Global Burden of Disease (GBD) 2023 data.
methodsAge-standardized incidence, mortality, and DALYs rates (ASIR, ASMR, and ASDR [age-standardized DALYs rate], respectively) and estimated annual percentage change (EAPC) were calculated for the three countries and globally. Segmented regression identified phase-specific inflections in incidence trends, decomposition analysis partitioned absolute changes into population growth, aging, and epidemiological contributions, and age-period-cohort (APC) analysis characterized drivers of ASDR. Attributable fractions ranked modifiable risk factors for cause-specific mortality.
resultsIn 2023, Japan had the highest ASIR (37.43 per 100,000) while China had the lowest (17.50 per 100,000); all three countries fell below the global ASMR and ASDR. China and the Republic of Korea achieved significant declines across all standardized rates, whereas Japan's near-null overall incidence trend concealed a marked late-period acceleration (2017-2023 APC = 0.86%). Globally, ASMR and ASDR rose significantly. Burden concentrated in adults aged 75-79 years and was consistently higher in males globally. Epidemiological change strongly offset demographic pressures in all three countries, and descriptive APC examination identified protective period- and cohort-related patterns in China and the Republic of Korea but an emerging adverse cohort-related pattern in Japan. High systolic blood pressure dominated attributable mortality (67%-89% in 2023), with the contribution of high body-mass index rising substantially over the study period.
conclusionThe burden of hypertension-attributed CKD has followed markedly divergent trajectories across East Asia, with Japan bearing a disproportionately high and recently accelerating incidence, underscoring the need for age-targeted screening and country-specific prevention strategies.
Indexed as
Identifiers
42704541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.